Immunotherapy in EGFR-Mutant and ALK-Positive Lung Cancer: Implications for Oncogene-Driven Lung Cancer

Area of Science:

• Oncology
• Immunotherapy
• Molecular Biology

Background:

• Non-small cell lung cancer (NSCLC) is characterized by diverse genetic alterations.
• Targeted therapies have improved outcomes for specific molecular subtypes of NSCLC.
• Acquired resistance to targeted therapies necessitates exploring alternative treatment strategies.

Purpose of the Study:

• To investigate the role and efficacy of immune checkpoint inhibitors (ICIs) in NSCLC patients with oncogenic driver mutations.
• To focus on epidermal growth factor receptor-mutant (EGFR-mutant) and anaplastic lymphoma kinase-rearranged (ALK-rearranged) NSCLC as models for this investigation.

Main Methods:

• Review of clinical data on programmed cell death 1 (PD-1) axis inhibitors in advanced NSCLC.
• Analysis of studies involving PD-1/PD-L1 inhibitor monotherapy.
• Examination of combination strategies including PD-(L)1 inhibitors with tyrosine kinase inhibitors (TKIs) and chemotherapy.

Main Results:

• The efficacy of PD-(L)1 inhibitors in NSCLC patients with oncogenic driver mutations is still under investigation.
• Clinical data on PD-(L)1 inhibitor monotherapy, and combinations with TKIs or chemotherapy are being evaluated.
• Understanding resistance mechanisms is crucial for optimizing immunotherapy in this patient population.

Conclusions:

• Immune checkpoint inhibitors represent a significant therapeutic advance in NSCLC.
• Further research is needed to clarify the optimal use of ICIs in EGFR-mutant and ALK-rearranged NSCLC.
• Combination therapies may hold promise for overcoming resistance and improving outcomes in oncogene-driven NSCLC.